- SID Score
- 7.9/10
- Fair value
- $122.76
- Generated
- Nov 17, 2026
- Model
- claude-haiku-4-5-20251001
AstraZeneca PLC trades at $184.02 with a market capitalization of $279.9 billion, demonstrating strong growth momentum but significant valuation concerns. The stock carries an elevated P/E ratio of 33.06x with a SID score of 7.9/10, indicating quality growth characteristics offset by weak value metrics. While analyst consensus remains "Buy" with an average price target of $102.67, the fair value estimate of $122.76 suggests substantial downside risk of 33.4% from current levels. The company exhibits strong earnings performance with recent EPS beats, though dividend yield of only 0.02% offers minimal income potential.
AstraZeneca demonstrates exceptional growth credentials with an A-grade rating and recent earnings that consistently exceed expectations, including a $2.79 EPS beat in October 2026 and $2.63 in July 2026 against lower estimates. However, the profitability grade of C and F-rated value metrics raise concerns about the sustainability of current valuations and underlying operational efficiency. The P/E ratio of 33.06x significantly exceeds typical healthcare sector averages, suggesting the market has priced in considerable future growth expectations that may be difficult to achieve. Without access to complete annual financial data, assessing return on equity, debt levels, and cash flow generation remains limited, though the strong earnings momentum indicates solid underlying business performance.
The stock's RSI(14) of 69.0 indicates overbought conditions, suggesting potential near-term pullback risk as the security approaches resistance levels. AstraZeneca trades above both its 50-day moving average of $169.23 and 200-day moving average of $179.67, confirming an established uptrend, though the stock's position near recent highs reduces upside confirmation from moving averages. The technical setup presents a conflicting picture: while price momentum appears strong, overbought RSI readings combined with the significant gap between current price and fair value estimates suggest consolidation or correction may be forthcoming. The momentum grade of A reflects this technical strength, though mean reversion toward the 200-day MA of $179.67 represents a potential 2.4% downside scenario.
Analyst & Insider Sentiment
Insider buying activity demonstrates moderate confidence, with Sharma Mani executing five purchase transactions between July and November 2026, including a significant 19,265-share acquisition on July 6th, suggesting management believes the stock offers value despite recent run-up. The "Buy" consensus among analysts appears contradictory given their average price target of $102.67, which implies 44.2% downside from current levels and raises questions about the credibility of consensus recommendations. This substantial disconnect between consensus ratings and price targets suggests analysts may be conflicted or slow to adjust ratings following the strong earnings performance. The neutral news sentiment indicates limited recent catalysts or negative headlines, reducing immediate sentiment-driven volatility.
Valuation represents the primary risk factor, as the current price of $184.02 significantly exceeds multiple fair value estimates ($122.76), leaving minimal margin of safety and high vulnerability to market corrections or disappointing forward guidance. The overbought RSI reading of 69.0 combined with earnings guidance risks creates potential for rapid price deterioration if future results fail to meet elevated market expectations built into the current valuation. Healthcare sector-specific risks include regulatory pressures, pipeline development uncertainties, patent expirations, and competitive pressures that could impact growth rates and justify lower valuation multiples. The minimal dividend yield of 0.02% provides no downside support through income generation, leaving the investment vulnerable to pure price-based volatility.
AstraZeneca presents a classic growth-at-too-high-a-price scenario where strong operational execution and earnings beats have been eclipsed by excessive valuation expansion to 33x earnings. Conservative investors should wait for meaningful pullbacks toward the $122.76-$179.67 price range before initiating positions, as current levels offer inadequate risk-reward compensation given overbought technicals and valuation disconnect with analyst targets. Growth-oriented investors with higher risk tolerance might selectively add on 5-10% corrections, particularly if insider buying continues and earnings maintain momentum, but current entry points warrant caution. The recommendation is to monitor for technical consolidation below $179.67 or watchlist for future pullbacks rather than accumulate at current prices where downside risk substantially outweighs upside potential.